With Overstretched FDA, Companies Advised To Conduct Their Own Foreign Inspections – Former FDA Chief Counsel

FDA's failure to inspect a Chinese API manufacturer that may be linked to the heparin safety issue will "drive home" to the pharmaceutical industry the need to ensure the safety of the ingredients in drug products, according to an industry expert